Safety and efficacy evaluation of gemcitabine combined with oxaliplatin for the treatment of patients with lymphoma / 中国实验血液学杂志

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the short-term efficacy and safety of GEMOX regimen for the treatment of lymphoma, so as to provide the reference for further rational selection of chemotherapy.</p><p><b>METHODS</b>A total of 61 patients with relapse and refractory non-Hodgkin's lymphoma (NHL) treated with chanotherapy of GEMOX regimen from 2010 Jannary -2013 year were selected, and their clinical data were collected, and the short-term efficacy, toxic effects and short-term survival were analyzed.</p><p><b>RESULTS</b>The improved rate of B symptom was 86.36%; the LDH level in 38 cases with high LDH level after chemotherapy all obviously decreased; the ORR and CBR in 64 patients after treatment were 68.75% and 87.50% respectively; the comparison of ORR and CBR between patients with different IPI score showed significantly statistical difference (P<0.05). The adverse reactions mainly observed in blood and digestive tract, but were mild; adverse reactions were reduced or disappeared after stoping drugs or symptomatic treatment. The median progression-free survival time of patients was 10.5 months.</p><p><b>CONCLUSION</b>Gemcitabine combined with oxaliplatin for treatment of relapse-refractory lymphoma shows singnificant efficacy and low toxicity, this regimen can be used as a second-line chemotheray in clinic.</p>